
BlueRock’s Cell Therapy for Parkinson’s Shows Positive 24-Month Data
Bayer AG and BlueRock Therapeutics, a subsidiary of Bayer, announced positive 24-month data from exPDite, a Phase 1 trial of bemdaneprocel, an investigational cell therapy for Parkinson’s disease. Bemdaneprocel is the most advanced cell therapy in the U.S. for Parkinson’s,…












